Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
Related Stories
Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 3 months
Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 3 months
Merck to acquire Terns Therapeutics for $6.7B / 3 months
Novartis buys Myricx Bio to bolster ADC ambitions / 7 hrs
Eli Lilly acquires CrossBridge Bio in oncology deal up to $300M / 2 months
UCB acquires Candid for $2B to pursue T‑cell engager therapies / 2 months
Chiesi acquires KalVista for $1.9B to bolster rare disease pipeline / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Eli Lilly, Pancreatic Cancer, Olfaction, Diagnostics and look for the RSS link.
StackHealth Time Machine